ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Garassino on Immunotherapy in EGFR-Mutated Lung Cancer

Marina Chiara Garassino, MD
Published: Wednesday, Nov 01, 2017



Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.

In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.
 


Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses immunotherapy for patients with EGFR-mutated lung cancer.

Looking at the subgroup analysis for all randomized clinical trials, there is no clear benefit in EGFR-mutated patients, making it difficult to decide whether to treat with immunotherapy or chemotherapy, explains Garassino.

In the ATLANTIC trial, patients with EGFR-mutated lung cancer were treated with durvalumab (Imfinzi). These patients experienced a benefit with progression-free survival and overall survival, states Garassino.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x